药物遗传学对特拉马多尔药物动力学的作用:一个人口药物动力学模型
Paula Soria-Chacartegui1, Gudrun Würthwein2, Pablo Zubiaur1
1Clinical Pharmacology Department, Hospital Universitario de La Princesa, Pharmacology Department, Faculty of Medicine, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria la Princesa (IIS-Princesa), Madrid, Spain.
European journal of drug metabolism and pharmacokinetics
|March 3, 2026
概括
药物遗传学会影响特拉马多尔的反应. 一种种群的药理动力学模型显示,CYP2D6中间代谢剂的特拉马多尔暴露率高出20-40%,影响了剂量策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物遗传学 药物遗传学
- 临床药房 临床药房
背景情况:
- 特拉马多尔是一种常见的阿片类止痛药.
- 特拉马多尔反应的个体变异部分是由于遗传因素.
- 开发一个包含药物遗传学的群体药理动力学 (popPK) 模型对于理解特拉马多尔变异性至关重要.
研究的目的:
- 为特拉马多尔开发一个人口药理动力学 (popPK) 模型.
- 将药物遗传信息,特别是CYP2D6,CYP2B6和CYP3A4表型整合到popPK模型中.
- 分析遗传变异对特拉马多尔药理动学的影响.
主要方法:
- 24名健康志愿者接受了单次口服特拉马多尔/易布洛芬剂量.
- 在24小时内收集血液样本进行药理动力学分析.
- 对关键药物基因进行基因定型,并使用NONMEM构建了一个popPK模型.
- 评估了CYP2D6,CYP2B6和CYP3A4表型对清除的影响.
主要成果:
- 一个两部分的模型最好地描述了特拉马多尔的药理动力学.
- 与正常/超快代谢剂 (NMs/UMs) 相比,CYP2D6中间代谢剂 (IMs) 的清除率降低了20%.
- 模拟预测CYP2D6 IMs中的特拉马多尔暴露率 (AUC) 提高了20-40%.
- CYP2B6和CYP3A4表型没有显著影响特拉马多尔清除.
结论:
- 一个包含CYP2D6表型的popPK模型准确地描述了特拉马多尔的药理动力学.
- CYP2D6基因型显著影响着特拉马多尔暴露.
- 需要进一步研究更大的样本大小,以探索CYP2B6和CYP3A4表型的临床相关性.
相关概念视频
01:12Analysis of Population Pharmacokinetic Data
933
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
933
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
379
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
379
01:29Pharmacogenetics and Pharmacogenomics: Overview
162
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
162
01:27Principles of Pharmacogenetics: Types of Genetic Variants
102
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
102
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
119
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
119
01:27Pharmacogenetics of Drug Metabolism: Overview
137
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
137